Autobio(SH:603658)2017-10-26 16:00Financial Performance - Operating revenue for the first nine months reached CNY 982,894,835.98, a 41.98% increase year-on-year[6] - Net profit attributable to shareholders was CNY 323,615,060.31, reflecting a 26.99% growth compared to the same period last year[6] - Basic and diluted earnings per share rose by 14.93% to CNY 0.77[7] - Total operating revenue for Q3 2017 reached ¥400,373,004.01, a 55% increase from ¥258,542,117.72 in the same period last year[30] - Operating profit for Q3 2017 was ¥153,005,448.00, up 25% from ¥122,354,572.38 year-over-year[30] - Net profit attributable to the parent company for Q3 2017 was ¥132,183,506.02, representing a 23% increase compared to ¥107,087,534.30 in Q3 2016[31] - Net profit for the first nine months of 2017 was ¥340,283,450.65, up 32.2% from ¥257,338,321.21 in the same period last year[34] - Total profit for Q3 2017 was ¥160,736,567.57, a 19.8% increase from ¥134,197,595.39 in Q3 2016[34] Cash Flow - Net cash flow from operating activities increased by 32.23% to CNY 349,301,211.22 for the first nine months[6] - Cash flow from operating activities for the first nine months of 2017 was ¥349,301,211.22, compared to ¥264,155,715.01 in the previous year, reflecting a 32.3% increase[36] - Operating cash inflow for the first nine months reached ¥1,101,574,122.07, up from ¥768,860,453.42 in the same period last year, representing a growth of approximately 43.2%[40] - Net cash flow from operating activities was ¥383,132,979.05, compared to ¥317,155,102.77 in the previous year, indicating an increase of about 20.8%[40] - Investment activities generated a net cash flow of ¥10,200,979.36 in the first nine months of 2017, compared to a negative cash flow of ¥125,184,056.31 in the same period last year[37] - Cash inflow from financing activities totaled ¥37,800,000.00, down from ¥594,434,885.00 in the previous year, indicating a reduction in financing activities[40] - Net cash flow from financing activities was -¥386,434,912.50, compared to ¥482,652,170.63 in the same period last year, reflecting a shift in financing strategy[40] Assets and Liabilities - Total assets increased by 11.12% to CNY 2,024,074,805.57 compared to the end of the previous year[6] - Current assets totaled 816,776,237.31 RMB, down from 1,175,086,777.99 RMB at the beginning of the year, indicating a decrease of about 30.5%[20] - Non-current assets increased to 1,207,298,568.26 RMB from 646,353,988.22 RMB, reflecting a growth of approximately 86.5%[21] - Total liabilities reached 466,346,844.53 RMB, up from 176,515,714.84 RMB, marking an increase of about 164.5%[22] - The company's equity attributable to shareholders decreased from 1,644,925,051.37 RMB to 1,544,340,111.68 RMB, a decline of approximately 6.1%[22] - Cash and cash equivalents decreased to 19,492,708.19 RMB from 56,211,534.93 RMB, a drop of about 65.3%[20] Investments and Acquisitions - Inventory increased by 66.82% to RMB 154,356,739.40, primarily due to the acquisition of Shengshi Junhui Biochemical's entire product line[14] - The company reported a significant increase in goodwill to RMB 164,648,504.26, reflecting the acquisition of Baiaotai Kang through a business combination[14] - The company established a new subsidiary in Hebei with a registered capital of RMB 10 million, holding 35.7% of the shares[16] - A new subsidiary, Hangzhou Antu Jiuhua Medical Technology Co., Ltd., was established with a registered capital of RMB 20 million, in which the company holds 51%[16] - The company established Heilongjiang Antu Jiuhe Biological Engineering Co., Ltd. with a registered capital of 10 million RMB, holding 51% of the shares[17] - The company increased its investment in Dian Tu by 8.925 million RMB, raising Dian Tu's registered capital from 35 million RMB to 60.5 million RMB[17] Expenses - The company's sales expenses rose by 46.84% to RMB 153,907,045.51, driven by increased salaries and the acquisition of Shengshi Junhui Biochemical's product line[15] - The company's total operating costs for the first nine months of 2017 were ¥357,694,899.76, an increase of 59.2% from ¥224,520,979.14 in the same period last year[33] - The company reported a financial expense of ¥1,262,910.07 for the first nine months of 2017, compared to a financial income of ¥3,837,581.13 in the previous year[33] Shareholder Information - The total number of shareholders reached 13,330 by the end of the reporting period[10] - The largest shareholder, Zhengzhou Antu Industrial Co., Ltd., holds 67.49% of the shares[11]